Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Macomics, a UK-based cancer immune therapy spinout of University of Edinburgh, has formally launched with $4m of seed funding led by Epidarex Capital with support from Scottish Investment Bank, a subsidiary of government-owned economic development agency Scottish Enterprise. Proceeds from the round will help identify immuno-oncological leads based on the concepts of Jeffrey Pollard, professor…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.